Eric Jung, MD
Retina Specialist · Encino, CANPI 1740749076
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 39.2% of the total. Reporting peaked in 2023 at $2,246 and has fallen 74.9% since, to $563 in 2025.
Across 43 payments — averaging $107.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Eyepoint US, Inc.$1K
- Alcon$376
- Alimera Sciences, Inc.$285
- AbbVie$253
- Apellis Pharmaceuticals, Inc.$218
- plus $476 from 5 others
What the payments were for
- Consulting fees$1,10024%
- Travel & lodging$89519%
- Food & beverage$2,63557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 18 | $1,816 |
| Eyepoint US, Inc. | 2 | $1,205 |
| Alcon | 4 | $376 |
| Alimera Sciences, Inc. | 2 | $285 |
| AbbVie | 6 | $253 |
| Apellis Pharmaceuticals, Inc. | 4 | $218 |
| Regeneron Healthcare Solutions, Inc. | 2 | $161 |
| Astellas Pharma US Inc | 1 | $119 |
| Procept Biorobotics Corporation | 2 | $111 |
| Regeneron | 1 | $67 |
| Glaukos Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,205
- STELLARIS ELITE$906
- Iluvien$285
- STELLARIS$226
- XIIDRA$161
- MIEBO$161
- OZURDEX$137
- Hydrus Microstent$135
- EYLEA HD$125
- Syfovre$122
- Constellation$110
- Clareon$108
How this compares
$4,630 in reported general payments places this provider in the 55th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 115 | $4,326 |
| Ciprofloxacin Hcl | 50 | $561 |
| Brimonidine Tartrate | 21 | $515 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $434 |
| Atropine Sulfate | 16 | $405 |
| Ofloxacin | 12 | $282 |
| Timolol Maleate | 12 | $242 |
| ErythromycinErythromycin Base | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Encino
- Jessica CaoEncino$11K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
- Michael JavaheriBeverly Hills$540K
- Esther KimSanta Ana$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.